



# Cyclica


## 2022 Year in Review



This November, we received a \$2.4M grant from the **Bill & Melinda Gates Foundation** to develop non-hormonal contraceptives for low-data targets.



In their annual edition, **Business Insider** named Cyclica among one of the "Top Biotech Startups set to take off in the next 12 months."



We published several posts revolving around our AlphaFold integration and the use of AI in drug discovery. Visit [blog.cyclicarx.com](https://blog.cyclicarx.com) for the full story.

We announced several **new partnerships** in both the **industry** and **academic** spaces this year.




Here are some of the other **press releases** and **case studies** we published this year.



Cyclica recruits big pharma veteran Michael Palovich as Chief Science Officer to advance robust drug discovery pipeline



Cyclica launches Perturba Therapeutics, a spin out from the University of Toronto, creating the next-generation oncology biotech



Cyclica CEO Naheed Kurji named Chair of the AAIH / Naheed Kurji appointed to OBIO Board of Directors




Entheogenix Biosciences (Cyclica & Atai Life Sciences joint venture) discovers novel 5-HT2A agonists

Visit us at [www.cyclicarx.com](https://www.cyclicarx.com) to read more.


We hosted several thought leadership discussions with industry experts about AI DD in our Molecule to Medicine Series.



We published a case study on the work we did, resulting in the first co-crystal structure published of DCAF1 in the PDB.



And we released a corporate manifesto on our evolved business plan and how we are opening new frontiers in drug discovery.



Unlocking the protein universe to discover the medicines of tomorrow.

Thank you to our partners and collaborators for being part of such a successful year.



From molecule to medicine